title: [The effects of ginsenosides Rg3 on the expressions of VEGF and KDR in human lung squamous cancer cells].
abstract: OBJECTIVE
  To investigate the inhibitive effects of Ginsenosides Rg3 (GS-Rg3) in the process of tumor angiogenesis and the effects on the expressions of VEGF and its receptor KDR in human lung squamous cancer SK-MES-1 cell line.
  
  
  METHODS
  Human lung cancer SK-MES-1 cells were cultured in vitro and immunocytochemistry and RT-PCR methods were used to detect the effects of different concentrations of Rg3 on the expressions of VEGF and KDR on SK-MES-1 cells.
  
  
  RESULTS
  The immunocytochemistry results showed that the positive rates of VEGF protein in different group of SK-MES-1 cells were 81.33 +/- 9.04, 61.80 +/- 7.98, 43.80 +/- 5.25, 29.77 +/- 8.04, respectively. The positive rates of KDR protein in different group of SK-MES-1 cells were 65.51 +/- 7.45, 51.73 +/- 9.21, 34.87 +/- 6.15, 22.04 +/- 5.11, respectively. There were significant differences between each group. RT-PCR results suggested that with the increase of the concentration of Rg3, VEGF and KDR amplified bands gradually weakened. There were significant differences between each group.
  
  
  CONCLUSIONS
  GS-Rg3 can down-regulate the expressions of KDR and VEGF protein and their mRNA in human lung squamous cancer SK-MES-1 cells. It may be one of the mechanisms in the process of inhibiting tumor angiogenesis.
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. wxgoal@163.com
authors.forename: Xin
authors.initials: X
authors.lastname: Wang
authors.forename: Yu-ling
authors.initials: YL
authors.lastname: Zheng
authors.forename: Ke
authors.initials: K
authors.lastname: Li
authors.forename: Na
authors.initials: N
authors.lastname: Lin
authors.forename: Qing-xia
authors.initials: QX
authors.lastname: Fan
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000494:pharmacology*; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000473:pathology; D045744:Cell Line, Tumor; D004305:Dose-Response Relationship, Drug; D036145:Ginsenosides / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000378:metabolism* / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000517:prevention & control; D005894:Panax / Q000737:chemistry; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism*; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000235:genetics / Q000378:metabolism*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D036145:Ginsenosides; D012333:RNA, Messenger; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C097367:ginsenoside Rg3; D040301:Vascular Endothelial Growth Factor Receptor-2